title: Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
abstract: Hepatocellular carcinoma (HCC) is a common cause of worldwide mortality. Transarterial radioembolization (TARE) with yttrium-90 (Y90), a transcatheter intra-arterial procedure performed by interventional radiology, has become widely utilized in managing HCC.
  
  
  
  The following is a focused review of TARE covering its commercially available products, clinical considerations of treatment, salient clinical trial data establishing its utility, and the current and future roles of TARE in the management of HCC.
  
  
  
  TARE is indicated for patients with unresectable, intermediate stage HCC. The two available products are glass and resin microspheres. All patients undergoing TARE must be assessed with a history, physical examination, clinical laboratory tests, imaging, and arteriography with macroaggregated albumin. TARE is safe and effective in the treatment of unresectable HCC, as it has a safer toxicity profile than chemoembolization, longer time-to-progression, greater ability to downsize and/or bridge patients to liver transplant, and utility in tumor complicated by portal vein thrombosis. TARE can also serve as an alternative to ablation and chemotherapy.
  
  
  
  TARE assumes an integral role in the management of unresectable HCC and has been validated by numerous studies.
authors.affiliation: Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
authors.forename: Joseph Ralph
authors.initials: JR
authors.lastname: Kallini
authors.affiliation: Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Gabr
authors.affiliation: Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.|Division of Transplantation, Department of Surgery, Comprehensive Transplant Center, Northwestern University, Chicago, IL, USA.|Division of Hematology and Oncology, Department of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
authors.forename: Riad
authors.initials: R
authors.lastname: Salem
authors.affiliation: Department of Radiology, Section of Interventional Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. r-lewandowski@northwestern.edu.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Lewandowski
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D019468:Disease Management; D004621:Embolization, Therapeutic / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D016896:Treatment Outcome; D015019:Yttrium / Q000494:pharmacology*; D015021:Yttrium Radioisotopes / Q000494:pharmacology
chemical_list: D015021:Yttrium Radioisotopes; D015019:Yttrium
keywords: Hepatocellular carcinoma (HCC); Oncology; Radioembolization; Transarterial radioembolization (TARE); Yttrium-90 (Y90)